Icatibant Sandoz

Icatibant, the active ingredient in Icatibant Sandoz, is a bradykinin B2 receptor antagonist presented as a subcutaneous formulation for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in patients with C1‑inhibitor deficiency.

GNH USA supplies Icatibant Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier, providing quality‑assured products to hospitals, pharmacies and clinics worldwide. The company follows stringent manufacturing standards and offers reliable logistics for global distribution.

Icatibant is used to manage hereditary angioedema, a disorder characterized by sudden swelling due to bradykinin excess.

- Hereditary angioedema (C1‑inhibitor deficiency) attacks: rapid reduction of swelling and pain during acute episodes. - Hereditary angioedema type I: shortens the duration of attacks and improves patient comfort. - Hereditary angioedema type II: facilitates faster symptom resolution in acute flare‑ups.

Icatibant may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: discomfort at the site of subcutaneous administration. - Redness at injection site: localized erythema. - Swelling at injection site: mild edema around the needle entry. - Nausea: transient feeling of queasiness. - Headache: mild to moderate head pain. - Flushing: temporary warmth and reddening of skin.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema: unexpected swelling of face, lips, or airway. - Hypotension: sudden drop in blood pressure. - Severe injection site reaction: necrosis or ulceration. - Thrombocytopenia: low platelet count observed in rare cases.

When prescribing Icatibant, clinicians should consider several safety precautions to minimize risk.

- Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown excretion; weigh benefits against possible infant exposure. - Renal impairment: no dosage adjustment required, but monitor for accumulation. - Concomitant ACE inhibitors: may increase risk of angioedema; observe closely. - Hypersensitivity: discontinue immediately if severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - ACE inhibitors: combined use may heighten risk of angioedema. - Renin‑angiotensin system blockers (ARBs, aliskiren): similar potential for increased angioedema. - Other bradykinin B2 antagonists: additive pharmacologic effect may lead to excessive blockade.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may influence bradykinin metabolism, requiring observation. - NSAIDs: can exacerbate swelling or pain in susceptible individuals. - DPP‑4 inhibitors: theoretical risk of altered bradykinin degradation; monitor clinical response.